All In Biotech

Drug Trial Radar · NCT06415214

Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes

A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HRS-7535 in Adults With Diabetic Kidney Disease in Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 281 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

281

Actual

Start

Jun 21, 2024

Primary completion

Jul 15, 2025

Study completion Jul 25, 2025

Sponsor

Sponsor type
Industry
First posted
May 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a 16-week multicenter, randomized, double-blind, placebo-controlled, parallel-designed Phase II clinical study. The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in subjects with diabetic kidney disease in type 2 diabetes.

Conditions

  • Diabetic Kidney Disease, Type 2 Diabetes

Interventions

  • PlaceboDrug

    Placebo

  • HRS-7535Drug

    HRS-7535

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio of UACR at week 16 to UACR at baselineTime frame: at Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.